Melissa Young, MD, PhD
Assistant Professor of Clinical Therapeutic Radiology; Medical Director, Trumbull Radiation Oncology Center, Therapeutic Radiology; Chief, Head and Neck Radiotherapy Program, Therapeutic Radiology
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.
- Optimizing a lupus autoantibody for targeted cancer therapy.Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a lupus autoantibody for targeted cancer therapy. Cancer Research 2015, 75: 2285-91. PMID: 25832653, DOI: 10.1158/0008-5472.CAN-14-2278.
- Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2015, 25: 431-9. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/IGC.0000000000000376.
- A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells.Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.